News

Pfizer Oncology will initiate a global, phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced

Vical has presented encouraging results from animal studies of a peptide-based cancer vaccine formulated with the Vaxfectin adjuvant. The study demonstrates the adjuvant’s ability to enhance immune responses

Morphotek has reported preliminary data from a phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab

DOR BioPharma has entered into common stock purchase agreements with institutional investors totaling approximately $3.85m. DOR’s North American commercial partner, Sigma-Tau Pharmaceuticals, participated in this financing. Under the

Paladin Labs has received approval from the Biologics and Genetic Therapies Directorate of Health Canada for GlucaGen (recombinant glucagon for injection). GlucaGen is indicated for the treatment of

LEO Pharma is re-acquiring Warner Chilcott’s exclusive product licensing rights in the US to its topical psoriasis treatments Taclonex, Taclonex Scalp, Dovonex as well as rights to all

SuiteMed Solutions is customising their SuiteMed EHR to facilitate receipt of patient data from ALR Technologies’ patented Health-E-Connect patient monitoring system. SuiteMed Solutions’ EHR package will also include

Sanofi Pasteur has approved the results of the collaborative HIV vaccine trial that has been conducted in Thailand over the past six years. The phase III clinical trial

Amgen has announced detailed results from the phase 3 ‘203’ trial evaluating Vectibix (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the first-line treatment of metastatic